{"name":"Zhibin Xu","slug":"zhibin-xu","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Sitagliptin and Gliclazide","genericName":"Sitagliptin and Gliclazide","slug":"sitagliptin-and-gliclazide","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Sitagliptin and Gliclazide","genericName":"Sitagliptin and Gliclazide","slug":"sitagliptin-and-gliclazide","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQY19kMEdUb0FVX01ZMDJGMkUxQWRBVmE0X3IwajJfYjJ6ZEdKZjZXT1BkTEtDb2lQbHNlNEFEOEJMMENJVUZQNlIxN2lySDNZd1NvVUdFY2hraVNxeDk1Q0k2R010S29OZTZwYk10M1dScjQxWGd0VzN0WnplOHU2OVEzTkNLRWpFd1ExZjdyY2xOOHFjN2dZcGtoRQ?oc=5","date":"2025-03-03","type":"pipeline","source":"Frontiers","summary":"Teprotumumab in the Management of Thyroid Eye Disease Mechanistic Insights and Adverse Reactions: A Comprehensive Review - Frontiers","headline":"Teprotumumab in the Management of Thyroid Eye Disease Mechanistic Insights and Adverse Reactions: A Comprehensive Review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE5jQjJ6NENvb25NOXYyUFYwQ0NlWHc1SUJGakV2d1dzVS1yNXN2cDBiMTROTi1WR1ZsMEpUenlqMjA5RGlJaUtfNG54YThIVHVweWxQSVpFcTBZVlgzNjM4SkVQdXp5NFA5Rk8xNGQ0SQ?oc=5","date":"2024-09-11","type":"pipeline","source":"Wiley Online Library","summary":"Controllable Multi-Exciton Zero-Dimensional Antimony-Based Metal Halides for White-light Emission and β-Ray Detection - Wiley Online Library","headline":"Controllable Multi-Exciton Zero-Dimensional Antimony-Based Metal Halides for White-light Emission and β-Ray Detection","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}